|
[1]
|
Saeedi, P., Petersohn, I., Salpea, P., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Pro-jections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Re-search and Clinical Practice, 157, Article ID: 107843. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ruiz-Ortega, M., Rodrigues-Diez, R.R., Lavoz, C., et al. (2020) Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”. Journal of Clinical Medicine, 9, 813. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304.
|
|
[4]
|
Saran, R., et al. (2020) US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 75, A6-A7.
|
|
[5]
|
Cheng, H.T., Xu, X., Lim, P.S., et al. (2021) Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015. Diabetes Care, 44, 89-97. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Wang, F., Yang, C., Long, J., et al. (2019) Executive Summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET). Kidney International, 95, 501-505. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Zuo, C. and Xu, G. (2019) Efficacy and Safety of Mineralocorticoid Receptor Antagonists with ACEI/ARB Treatment for Diabetic Nephrop-athy: A Meta-Analysis. International Journal of Clinical Practice, e13413. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Jaisser, F. and Farman, N. (2016) Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacological Reviews, 68, 49-75. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Guichard, J.L., Clark, D., Calhoun, D.A., et al. (2013) Aldosterone Receptor Antagonists: Current Perspectives and Therapies. Vascular Health and Risk Management, 9, 321-331. [Google Scholar] [CrossRef]
|
|
[10]
|
Yang, P., Huang, T. and Xu, G. (2016) The Novel Mineralocorticoid Receptor Antagonist Finerenone in Diabetic Kidney Disease: Progress and Challenges. Metabolism, 65, 1342-1349. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Shrestha, A., Che, R.C. and Zhang, A.H. (2019) Role of Al-dosterone in Renal Fibrosis. Advances in Experimental Medicine and Biology, 1165, 325-346. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Young, M.J. and Rickard, A.J. (2015) Mineralocorticoid Re-ceptors in the Heart: Lessons from Cell-Selective Transgenic Animals. Journal of Endocrinology, 224, R1-13. [Google Scholar] [CrossRef]
|
|
[13]
|
Fraccarollo, D., Berger, S., Galuppo, P., et al. (2011) Deletion of Car-diomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling after Myocardial Infarction. Circulation, 123, 400-408. [Google Scholar] [CrossRef]
|
|
[14]
|
Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. (2017) Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045. [Google Scholar] [CrossRef]
|
|
[15]
|
Nishiyama, A. (2019) Pathophysiological Mechanisms of Mineralocorticoid Receptor-Dependent Cardiovascular and Chronic Kidney Disease. Hypertension Research, 42, 293-300. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Mongia, A., Vecker, R. and George, M., et al. (2012) Role of 11betaHSD Type 2 Enzyme Activity in Essential Hypertension and Children with Chronic Kidney Disease (CKD). The Journal of Clinical Endocrinology & Metabolism, 97, 3622-3629. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Gant, C.M., Minovic, I., Binnenmars, H., et al. (2018) Lower Renal Function Is Associated with Derangement of 11-beta Hydroxysteroid Dehydrogenase in Type 2 Diabetes. Journal of the Endocrine Society, 2, 609-620. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Nagase, M. and Fujita, T. (2013) Role of Rac1-Mineralocorticoid-Receptor Signalling in Renal and Cardiac Disease. Nature Reviews Nephrology, 9, 86-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Kawarazaki, W. and Fujita, T. (2021) Kidney and Epigenetic Mecha-nisms of Salt-Sensitive Hypertension. Nature Reviews Nephrology, 17, 350-363. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Hall, J.E., Do Carmo, J.M., Da Silva, A.A., et al. (2019) Obesity, Kidney Dysfunction and Hypertension: Mechanistic Links. Nature Reviews Nephrology, 15, 367-385. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Quinkler, M., Zehnder, D., Eardley, K.S., et al. (2005) Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients with Heavy Proteinuria. Circula-tion, 112, 1435-1443. [Google Scholar] [CrossRef]
|
|
[22]
|
Staessen, J., Lijnen, P., Fagard, R., et al. (1981) Rise in Plasma Concentration of Aldosterone during Long-Term Angiotensin II Suppression. Journal of Endocrinology, 91, 457-465. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Navaneethan, S.D. and Bravo, E.L. (2013) Aldosterone Breakthrough during Angiotensin Receptor Blocker Use: More Questions than Answers? Clinical Journal of the Ameri-can Society of Nephrology, 8, 1637-1639. [Google Scholar] [CrossRef]
|
|
[24]
|
Barry, M.B., Renner, M.D. and Mark, E. (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 345, 12. [Google Scholar] [CrossRef]
|
|
[25]
|
Shunan, F., Jiqing Y., Xue D. (2018) Effects of Angioten-sin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Cardiovascular Events in Patients with Diabe-tes and Overt Nephropathy: A Meta-Analysis of Randomised Controlled Trials. Journal of the Ren-in-Angiotensin-Aldosterone System, 19, 1-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Bomback, A.S. and Klemmer, P.J. (2007) The Incidence and Im-plications of Aldosterone Breakthrough. Nature Clinical Practice Nephrology, 3, 486-492. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Parving, H.H., Brenner, B.M., Mcmurray, J.J., et al. (2012) Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. The New England Journal of Medicine, 367, 2204-2213. [Google Scholar] [CrossRef]
|
|
[28]
|
Fried, L.F., Emanuele, N., Zhang, J.H., et al. (2013) Combined An-giotensin Inhibition for the Treatment of Diabetic Nephropathy. The New England Journal of Medicine, 369, 1892-1903. [Google Scholar] [CrossRef]
|
|
[29]
|
Bauersachs, J., Jaisser, F. and Toto, R. (2015) Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension, 65, 257-263. [Google Scholar] [CrossRef]
|
|
[30]
|
Mora-Fernandez, C., Dominguez-Pimentel, V., De Fuentes, M.M., et al. (2014) Diabetic Kidney Disease: From Physiology to Therapeutics. The Journal of Physiology, 592, 3997-4012. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Mehdi, U.F., Adams-Huet, B., Raskin, P., et al. (2009) Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angioten-sin-Converting Enzyme Inhibition in Diabetic Nephropathy. Journal of the American Society of Nephrology, 20, 2641-2650. [Google Scholar] [CrossRef]
|
|
[32]
|
Esteghamati, A., Noshad, S., Jarrah, S., et al. (2013) Long-Term Effects of Addition of Mineralocorticoid Receptor Antagonist to Angiotensin II Receptor Blocker in Patients with Diabetic Nephropathy: A Randomized Clinical Trial. Nephrology Dialysis Transplantation, 28, 2823-2833. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Makhlough, A., Kashi, Z., Akha, O., et al. (2014) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan. Nephro-Urology Monthly, 6, e12148. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Hou, J., Xiong, W., Cao, L., et al. (2015) Spironolactone Add-On for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-Analysis. Clinical Therapeutics, 37, 2086-2103e2010. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Tofte, N., Lindhardt, M., Adamova, K., et al. (2020) Early De-tection of Diabetic Kidney Disease by Urinary Proteomics and Subsequent Intervention with Spironolactone to Delay Progression (PRIORITY): A Prospective Observational Study and Embedded Randomised Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 8, 301-312. [Google Scholar] [CrossRef]
|
|
[36]
|
Pitt, B., Zannad, F., Remme, W.J., et al. (1999) The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine, 341, 709-717. [Google Scholar] [CrossRef]
|
|
[37]
|
Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. (2014) Spiro-nolactone for Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine, 370, 1383-1392. [Google Scholar] [CrossRef]
|
|
[38]
|
Funder, J.W. (2019) Aldosterone Research: 65 Years, and Counting. Vitamins and Hormones, 109, 1-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Kolkhof, P., Jaisser, F., Kim, S.Y., et al. (2017) Steroidal and Novel Non-Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handbook of Experimental Pharmacology, 243, 271-305. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Epstein, M., Buckalew, V. and Martinez, F. (2002) OR-54: Antipro-teinuric Efficacy of Eplerenone, Enalapril, and Eplerenone/Enalapril Combination Therapy in Diabetic Hypertensives with Microalbuminuria. American Journal of Hypertension, 15, 24A. [Google Scholar] [CrossRef]
|
|
[41]
|
Epstein, M., Williams, G.H., Weinberger, M., et al. (2006) Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes. Clinical Journal of the American Society of Nephrology, 1, 940-951. [Google Scholar] [CrossRef]
|
|
[42]
|
El Mokadem, M., Abd El Hady, Y. and Aziz, A. (2020) A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy. Cardi-orenal Medicine, 10, 392-401. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Brandt-Jacobsen, N.H., Johansen, M.L., Rasmussen, J., et al. (2021) Ef-fect of High-Dose Mineralocorticoid Receptor Antagonist Eplerenone on Urinary Albumin Excretion in Patients with Type 2 Diabetes and High Cardiovascular Risk: Data from the MIRAD Trial. Diabetes & Metabolism, 47, Article ID: 101190. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Hu, H., Zhao, X., Jin, X., et al. (2022) Efficacy and Safety of Eplerenone Treatment for Patients with Diabetic Nephropathy: A Meta-Analysis. PLOS ONE, 17, e0265642. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Pitt, B.R.W., Zannad, F., et al. (2003) Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. The New England Jour-nal of Medicine, 348, 1309-1321. [Google Scholar] [CrossRef]
|
|
[46]
|
Zannad, F.M.J. and Krum, H. (2011) Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. The New England Journal of Medicine, 364, 11-21. [Google Scholar] [CrossRef]
|
|
[47]
|
Amazit, L., Le Billan, F., Kolkhof, P., et al. (2015) Finerenone Im-pedes Aldosterone-Dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. Journal of Biological Chemistry, 290, 21876-21889. [Google Scholar] [CrossRef]
|
|
[48]
|
Agarwal, R., Kolkhof, P., Bakris, G., et al. (2021) Steroidal and Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Medicine. European Heart Journal, 42, 152-161. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Pitt, B., Kober, L., Ponikowski, P., et al. (2013) Safety and Tolera-bility of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease: A Randomized, Double-Blind Trial. European Heart Journal, 34, 2453-2463. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Bakris, G.L., Agarwal, R., Chan, J.C., et al. (2015) Effect of Finere-none on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial. JAMA, 314, 884-894. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Bakris, G.L., Agarwal, R., Anker, S.D., et al. (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 383, 2219-2229. [Google Scholar] [CrossRef]
|
|
[52]
|
Pitt, B., Anker, S.D., Bohm, M., et al. (2015) Rationale and Design of MinerAlocorticoid Receptor Antagonist Tolerability Study-Heart Failure (ARTS-HF): A Randomized Study of Finerenone vs. Eplerenone in Patients Who Have Worsening Chronic Heart Failure with Diabetes and/or Chronic Kidney Disease. European Journal of Heart Failure, 17, 224-232. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Pitt, B., Filippatos, G., Agarwal, R., et al. (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England Journal of Medicine, 385, 2252-2263. [Google Scholar] [CrossRef]
|
|
[54]
|
Wada, T., Inagaki, M., Yoshinari, T., et al. (2021) Apararenone in Patients with Diabetic Nephropathy: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Response Study and Open-Label Extension Study. Clinical and Experimental Nephrology, 25, 120-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Ito, S., Shikata, K., Nangaku, M., et al. (2019) Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Dou-ble-Blind, Placebo-Controlled, Phase II Trial. Clinical Journal of the American Society of Nephrology, 14, 1161-1172. [Google Scholar] [CrossRef]
|
|
[56]
|
Ito, S., Kashihara, N., Shikata, K., et al. (2020) Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clinical Journal of the American Society of Nephrology, 15, 1715-1727. [Google Scholar] [CrossRef]
|
|
[57]
|
Wu, Y., Lin, H., Tao, Y., et al. (2022) Network Meta-Analysis of Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease. Frontiers in Pharmacology, 13, Article ID: 967317. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127. [Google Scholar] [CrossRef] [PubMed]
|